KevinMD December 6, 2024
Richard A. Lawhern, PhD

On May 9-10, 2017, the U.S. Food and Drug Administration (FDA) held a workshop titled “Training health care providers on pain management and safe use of opioid analgesics — exploring the path forward.” I attended the workshop in person to offer comments on behalf of chronic pain patients. A summary of my observations at the time was published by the now-defunct Pain News Network. The following extended extract is from workshop proceedings published on May 9, 2017, by the FDA.

To begin this short presentation, I would draw the attention of the members in front [of the workshop] to the fact that, at present, millions of people either hypermetabolize or poorly metabolize opioid medications. This is due to variations...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: FDA, Govt Agencies
Supporting the Development of Drugs for Rare Diseases — The Importance of Regulatory Transparency
Opinion: To fight for those with rare diseases, Trump must reform and modernize the FDA thoughtfully
5 Rare Diseases That Now Have Their First FDA-Approved Treatments
This Bill Could Make It Legal for AI to Prescribe Medicine
STAT+: Trump’s FDA navigates layoffs, exits, and a new hire

Share This Article